Cantor Fitzgerald analyst Kristen Kluska lowered the firm’s price target on Sarepta to $158 from $165 and keeps an Overweight rating on the shares following the Q1 results. Sarepta’s team remains confident that SRP-9001 could have profound effects on patients, and it highlighted it may take 1-2 quarters before there is a significant ramp in sales, if approved, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- Sarepta Therapeutics reports Q1 adjusted EPS (97c), consensus ($1.38)
- SRPT Upcoming Earnings Report: What to Expect?
- Sarepta initiated with an Outperform at SMBC Nikko
- William Blair biotech analyst to hold an analyst/industry conference call
- Catalent concerns ‘may be overstated’ for Sarepta, says RBC Capital